TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.
About TherVacB
For Patients
TherVacB Team
Partners
European countries
Project duration (months)
World Hepatitis Day 2021 … because hepatitis can’t wait!
Every 30 seconds one person is dying from a hepatitis related illness. During the COVID-19 pandemic, there is a growing need to accelerate hepatitis elimination efforts. The TherVacB project team in Europe and Tanzania, working of clinical trial preparation on viral...
European Testing Week 14-21 May 2021
In times of COVID-19, European Testing Week aims to increase integrated testing efforts & promote awareness on the benefits of hepatitis and HIV testing! This Spring European Testing Week 2021 and with COVID-19, we won’t be going back to “testing as usual”. Find...
TherVacB website now available in four languages
Translations of the revised TherVacB website are now available in four languages! To make info about the TherVacB vaccination study and the European HBV Registry more accessible to a Europen audience, we have partnered with researchers at study centres to produce this...
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
📢EASL’s new Position Paper provides guidance on systemic #treatment of #livercancer
By @bruixj @StephenLChan1 Peter R. Galle @LorenzaRimassa & Bruno Sangro
➡️
Published in @JHepatology, it complements previous EASL Clinical Practice Guidelines
@EASLedu
New EASL Position Paper provides guidance on systemic treatment of liver cancer - EASL-The Home of Hepatology.
The Journal of Hepatology published a new free-access EASL Position Paper, titled, “Systemic treatment of hepatoce...
easl.eu
#Hepatitis is one of the most prevalent and serious infectious diseases in the world, affecting hundreds of millions of people. Help us put a stop to these preventable deaths by signing up to our #NOhep movement: http://www.nohep.org/join-us/
Thanks to the efforts of organisations like the Flagstaff International Relief Effort Mongolia is in the race to become the first country to eliminate #hepatitis!
Learn more about it in their #FindTheMissingMillions case study: https://bit.ly/3jlxPKB
@HepBFoundation has started the first global #registry to collect stories and experiences of #discrimination based on #hepatitis B or D status. Does this describe you? We would love to hear from you! Share your experiences at http://ow.ly/FV8j50FQ0d5
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848223.